Kiniksa exec sells 4,600 shares at $80.30

Kiniksa’s chief accounting officer reported option and RSU grants, RSU conversions, a 10b5-1 plan sale, and shares delivered or withheld for exercise price or tax obligations.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) disclosed that Chief Accounting Officer Michael R. Megna reported multiple equity transactions. On September 3, 2026, he sold 4,600 Class A Ordinary Shares at $80.30 per share under a Rule 10b5-1 trading plan executed on May 24, 2025. On September 1, 2026, he received a grant of 3,650 Restricted Share Units and a grant of 14,600 share options exercisable at $79.28 per share, plus several RSU conversions into Class A Ordinary Shares and a disposition of 5,531 shares at $79.28 for payment of exercise price or tax liability. He also voluntarily reported acquiring 279 shares at $33.50 on July 15, 2026 under the 2018 Employee Share Purchase Plan.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 13 txns

Insider Megna Michael R

Role CHIEF ACCOUNTING OFFICER

Sold 4,600 shs ($369K)

Approx. gross sale proceeds $369K

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Share F3	4,600	$80.30	$369K
Grant/Award	Restricted Share Unit F2, F4	3,650	$0.00	$0.00
Grant/Award	Share Option F5	14,600	$0.00	$0.00
Exercise	Restricted Share Unit F2, F6	2,644	$0.00	$0.00
Exercise	Restricted Share Unit F2, F7	2,362	$0.00	$0.00
Exercise	Restricted Share Unit F2, F8	2,558	$0.00	$0.00
Exercise	Restricted Share Unit F2, F9	3,932	$0.00	$0.00
Exercise	Class A Ordinary Share F2	3,932	--	--
Exercise	Class A Ordinary Share F2	2,558	--	--
Exercise	Class A Ordinary Share F2	2,362	--	--
Exercise	Class A Ordinary Share F2	2,644	--	--
Exercise Price or Tax Liability	Class A Ordinary Share	5,531	$79.28	$438K
Grant/Award	Class A Ordinary Share F1	279	$33.50	$9K

Holdings After Transaction: Restricted Share Unit — 18,863 contracts (Direct); Share Option — 14,600 contracts (Direct); Class A Ordinary Share — 29,062 shares (Direct)

Footnotes (9)

1. F1. The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2026 to July 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e).
2. F2. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
3. F3. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025.
4. F4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.
5. F5. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
6. F6. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
7. F7. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024.
8. F8. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
9. F9. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

Key Figures

Shares sold: 4,600 Class A Ordinary Shares Sale price: $80.30 per share RSU grant: 3,650 Restricted Share Units +5 more

8 metrics

Shares sold 4,600 Class A Ordinary Shares Sale on September 3, 2026 by Michael R. Megna

Sale price $80.30 per share 4,600-share sale on September 3, 2026

RSU grant 3,650 Restricted Share Units Granted on September 1, 2026, each for one Class A Ordinary Share

Share option grant 14,600 options Granted on September 1, 2026, exercisable into Class A Ordinary Shares

Option exercise price $79.28 per share 14,600-share option grant expiring August 31, 2036

Shares for exercise price or tax liability 5,531 Class A Ordinary Shares Code F transaction on September 1, 2026 at $79.28 per share

RSUs converted 11,496 Restricted Share Units Four RSU conversion transactions totaling 2,644, 2,362, 2,558 and 3,932 shares on September 1, 2026

ESPP acquisition 279 Class A Ordinary Shares at $33.50 Acquired July 15, 2026 under 2018 Employee Share Purchase Plan

Key Terms

Restricted Share Unit, Rule 16b-3(e), 10b5-1 plan, Employee Share Purchase Plan, +1 more

5 terms

Restricted Share Unit financial

"Each Restricted Share Unit (RSU) represents a contingent right"

A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.

Rule 16b-3(e) regulatory

"The acquisition of these shares was exempt pursuant to Rule 16b-3(e)"

10b5-1 plan regulatory

"This transaction was effected pursuant to a 10b5-1 plan executed"

A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.

Employee Share Purchase Plan financial

"pursuant to the Issuer's 2018 Employee Share Purchase Plan"

A program that lets employees buy their employer’s stock, often through regular payroll deductions and sometimes at a discounted price or with matching contributions; think of it as a company-run savings plan that converts part of pay into ownership. It matters to investors because it can increase insider ownership and employee motivation, potentially affecting company performance, and can slightly change share supply when new stock is issued or sold.

exercise price financial

"payment of exercise price or tax liability by delivering or withholding"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

What insider transactions did KNSA report for Michael R. Megna on this Form 4?

Kiniksa reported a sale of 4,600 Class A Ordinary Shares at $80.30, new grants of 3,650 RSUs and 14,600 share options at $79.28, several RSU conversions into shares, a 5,531-share disposition for exercise price or tax liability, and an earlier ESPP share acquisition.

Was the KNSA insider sale by Michael R. Megna made under a Rule 10b5-1 plan?

Yes. The filing states the 4,600-share sale on September 3, 2026 was effected pursuant to a Rule 10b5-1 plan executed by Michael R. Megna on May 24, 2025, and the Rule 10b5-1 affirmation checkbox is marked for the filing.

What new equity awards did KNSA grant to Michael R. Megna on September 1, 2026?

On September 1, 2026, Michael R. Megna received 3,650 Restricted Share Units, each representing one Class A Ordinary Share, and 14,600 share options with an exercise price of $79.28 per share, expiring on August 31, 2036, subject to the vesting schedule described in the footnotes.

What RSU vesting and conversions did KNSA disclose for Michael R. Megna?

The Form 4 reports multiple RSU exercises/conversions on September 1, 2026 of 2,644, 2,362, 2,558, and 3,932 RSUs into an equal number of Class A Ordinary Shares, tied to RSU grants from September 1, 2022, 2023, 2024, and 2025 vesting over four-year schedules.

How many KNSA shares were delivered or withheld for exercise price or tax liability?

The filing reports a code F transaction on September 1, 2026 in which 5,531 Class A Ordinary Shares at $79.28 per share were delivered or withheld for payment of exercise price or tax liability related to equity awards.

What shares did Michael R. Megna acquire under KNSA’s Employee Share Purchase Plan?

He voluntarily reported acquiring 279 Class A Ordinary Shares at $33.50 per share on July 15, 2026 under Kiniksa’s 2018 Employee Share Purchase Plan for the purchase period from January 16, 2026 to July 15, 2026, an acquisition exempt under Rule 16b-3(e).

What is the vesting schedule for Michael R. Megna’s new KNSA RSU and option awards?

The 3,650 RSUs granted September 1, 2026 vest over four years, with 25% vesting on each yearly anniversary of the grant date. The 14,600-share option vests 25% on the first anniversary of September 1, 2026 and then in 36 equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 05:52 PM Accepted by SEC EDGAR 09/03/2026 - 04:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Megna Michael R

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON W1J 7NJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF ACCOUNTING OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	07/15/2026		A(1)		279	A	$33.5	27,697	D
Class A Ordinary Share	09/01/2026		M		3,932	A	(2)	31,629	D
Class A Ordinary Share	09/01/2026		M		2,558	A	(2)	34,187	D
Class A Ordinary Share	09/01/2026		M		2,362	A	(2)	36,549	D
Class A Ordinary Share	09/01/2026		M		2,644	A	(2)	39,193	D
Class A Ordinary Share	09/01/2026		F		5,531	D	$79.28	33,662	D
Class A Ordinary Share	09/03/2026		S(3)		4,600	D	$80.3	29,062	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Unit	(2)	09/01/2026		A		3,650		(4)	(4)	Class A Ordinary Share	3,650	$0	3,650	D
Share Option	$79.28	09/01/2026		A		14,600		(5)	08/31/2036	Class A Ordinary Share	14,600	$0	14,600	D
Restricted Share Unit	(2)	09/01/2026		M			2,644	(6)	(6)	Class A Ordinary Share	2,644	$0	7,931	D
Restricted Share Unit	(2)	09/01/2026		M			2,362	(7)	(7)	Class A Ordinary Share	2,362	$0	4,725	D
Restricted Share Unit	(2)	09/01/2026		M			2,558	(8)	(8)	Class A Ordinary Share	2,558	$0	2,557	D
Restricted Share Unit	(2)	09/01/2026		M			3,932	(9)	(9)	Class A Ordinary Share	3,932	$0	0	D

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2026 to July 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e).

2. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

3. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025.

4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.

5. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.

6. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.

7. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024.

8. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.

9. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

	/s/ Douglas Barry, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)